Roivant Sciences Balance Sheet Health
Financial Health criteria checks 6/6
Roivant Sciences has a total shareholder equity of $5.6B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.2B and $626.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.39b |
| Equity | US$5.58b |
| Total liabilities | US$625.99m |
| Total assets | US$6.21b |
Recent financial health updates
No updates
Recent updates
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Feb 05Roivant Sciences: A Biotech Growth Play With Major Ambitions
Dec 04Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Oct 22Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position
Aug 22
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21Financial Position Analysis
Short Term Liabilities: ROIV's short term assets ($5.8B) exceed its short term liabilities ($556.2M).
Long Term Liabilities: ROIV's short term assets ($5.8B) exceed its long term liabilities ($69.7M).
Debt to Equity History and Analysis
Debt Level: ROIV is debt free.
Reducing Debt: ROIV has no debt compared to 5 years ago when its debt to equity ratio was 10.6%.
Debt Coverage: ROIV has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ROIV has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 13:39 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roivant Sciences Ltd. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Chi Meng Fong | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |